According to the Zhitong Finance App, Zhongsheng Beikong Biotechnology (08247) released results for the nine months ended September 30, 2023, with operating income of 2106 million yuan (RMB, same below), a year-on-year decrease of 23.6%; parent company owners accounted for losses of 5.993 million yuan, profit for the same period last year; basic loss of 0.041 yuan per share.
During the reporting period, the company completed a total of 42 types of II products, including the glycated serum protein assay kit (NBT method) and 7 Class III products, including the herpes simplex virus type 1 IgG antibody test kit (chemiluminescence method), and nine Class III products, including the α-L-fucosidase assay kit (CNPF substrate method) and the herpes simplex virus type 1 IgG antibody test kit (chemiluminescence method), received renewal registration.